Lebenthal Global Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-13,888
Closed -$626K 187
2025
Q3
$626K Sell
13,888
-452
-3% -$21.1K 0.11% 126
2025
Q2
$664K Buy
14,340
+544
+4% +$26.7K 0.12% 119
2025
Q1
$841K Buy
13,796
+119
+0.9% +$6.94K 0.16% 85
2024
Q4
$774K Buy
13,677
+354
+3% +$19.8K 0.14% 102
2024
Q3
$689K Buy
13,323
+2,178
+20% +$102K 0.14% 100
2024
Q2
$463K Buy
11,145
+37
+0.3% +$1.66K 0.1% 121
2024
Q1
$602K Buy
11,108
+218
+2% +$11.1K 0.13% 97
2023
Q4
$559K Buy
10,890
+1,714
+19% +$90K 0.13% 101
2023
Q3
$533K Sell
9,176
-732
-7% -$44.9K 0.16% 76
2023
Q2
$634K Sell
9,908
-625
-6% -$41.9K 0.18% 58
2023
Q1
$730K Buy
10,533
+156
+2% +$11K 0.22% 42
2022
Q4
$747K Buy
10,377
+2,096
+25% +$158K 0.25% 36
2022
Q3
$588K Buy
8,281
+472
+6% +$34.2K 0.27% 44
2022
Q2
$601K Buy
+7,809
New +$595K 0.29% 55
2022
Q1
Sell
-8,136
Closed -$507K 152
2021
Q4
$507K Buy
+8,136
New +$477K 0.21% 76
2021
Q3
Sell
-15,150
Closed -$1.01M 135
2021
Q2
$1.01M Buy
+15,150
New +$988K 0.54% 24
2021
Q1
Sell
-5,195
Closed -$322K 181
2020
Q4
$322K Buy
+5,195
New +$319K 0.23% 59

Other funds holding BMY

Lebenthal Global Advisors's BMY Position: Q4 2025 in Review

Lebenthal Global Advisors sold out of Bristol-Myers Squibb (BMY) in Q4 2025, closing a stake of 13,888 shares — an estimated $626K sold.

Lebenthal Global Advisors first reported a position in BMY in Q4 2020 and held it in 17 quarters. The position peaked at $1.01M in Q2 2021. 2,447 funds tracked by Wall St. Rank hold BMY as of Q4 2025.

  • Lebenthal Global Advisors reported no remaining Bristol-Myers Squibb position as of Q4 2025 after selling out during the quarter.
  • Lebenthal Global Advisors sold 13,888 Bristol-Myers Squibb shares in Q4 2025, an estimated $626K.
  • Lebenthal Global Advisors first reported a position in Bristol-Myers Squibb in Q4 2020 and held it in 17 quarters.
  • Lebenthal Global Advisors's Bristol-Myers Squibb position peaked at $1.01M in Q2 2021.
  • 2,447 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2025.

Based on Lebenthal Global Advisors's 13F filing for Q4 2025, filed 28 Jan 2026.